Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

VE303 for Treatment of Hepatic Encephalopathy (HE)

NCT04899115
Conditions
Cirrhosis, Hepatic Encephalopathy
Interventions
Placebo, VE303, oral vancomycin
Drug
Lead sponsor
Patricia Bloom
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection, C.Difficile Diarrhea, Diarrhea Infectious
Interventions
VE303, Placebo
Biological
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
12 Years and older
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more
Conditions
Clostridium Difficile Infection Recurrence, Clostridium Difficile Infection, Clostridium Difficile, Clostridioides Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile, CDI
Interventions
VE303, Placebo
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Canoga Park, California + 22 more
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-human Study of VE303 in Healthy Adult Volunteers

NCT04236778
Conditions
Healthy Volunteers
Interventions
VE303, Oral Vancomycin
Drug
Lead sponsor
Vedanta Biosciences, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland